ASRT
Assertio Holdings, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$23.50
+0.00%Year over year
Reported trailing growth
- Revenue
- -14.2%
- EBITDA
- —
- EBIT
- +31.2%
- EPS
- -15.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -8.7%
- EBITDA
- -67.3%
- EBIT
- +29.6%
- Net income
- -40.7%
- EPS
- -37.4%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026